更新于：2024-06-24
Milrinone Lactate
乳酸米力农
更新于：2024-06-24
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1987-12-31), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看首次获批时间轴
结构
分子式C15H15N3O4 |
InChIKeyVWUPWEAFIOQCGF-UHFFFAOYSA-N |
CAS号100286-97-3 |
关联
73
项与 乳酸米力农 相关的临床试验Milrinone on Cardiac Performance in Patients Undergoing Off-pump Coronary Artery Bypass Surgery
Myocardial Reserve in Advanced Heart Failure Patients
Effect of Milrinone on the Right Ventricular Strain in Cardiac Surgery
100 项与 乳酸米力农 相关的临床结果
登录后查看更多信息
100 项与 乳酸米力农 相关的转化医学
登录后查看更多信息
100 项与 乳酸米力农 相关的专利（医药）
登录后查看更多信息
2,303
项与 乳酸米力农 相关的文献（医药）2024-03-01Journal of cardiothoracic and vascular anesthesia
Safety of Levosimendan in Pediatric Patients: An Up-to-Date Systematic Review
Review
作者: Belletti, Alessandro ; Bohane, Shai Marc ; Pusceddu, Elisabetta ; Silvetti, Simona ; Pilia, Eros
BACKGROUND:
The potential risks associated with the use of levosimendan in the pediatric population has not been systematically evaluated. This study aimed to review the available evidence regarding the safety of this treatment.
METHODS:
Bio Med Central, PubMed, Embase, and the Cochrane Central Register of clinical trials were searched for studies describing levosimendan administration in the pediatric population in any setting. Relevant studies were independently screened, selected, and their data extracted by two investigators. The authors excluded: reviews, meta-analyses, as well as basic research and trials involving patients >18 years old. The primary outcome was the number and the type of adverse side effects reported during levosimendan administration.
RESULTS:
The updated systematic review included 48 studies, enrolling a total of 1,271 pediatric patients who received levosimendan as treatment (790 patients in the 11 studies that reported side effects). The primary adverse effects of levosimendan administration were hypotension and cardiac arrhythmias, particularly tachycardia. Hypotension occurred in approximately 28.9% of patients, while arrhythmia occurred in about 12.3% of patients. Meta analysis of RCTs revealed a rate of all-cause mortality of 2.0% (8 out of 385) in the levosimendan group compared to 3.9% (15 out of 378) in the control group (dobutamine, milrinone or placebo) (risk ratio [RR] = 0.55; 95% confidence interval [CI] = 0.25-1.21; P = 0.14; I2 = 0%) CONCLUSIONS: Hypotension and cardiac arrhythmia are the most reported side effects of levosimendan in pediatric patients. However, adverse events remain underreported, especially in randomized trials.
2024-02-01Paediatric anaesthesia
Neurogenic myocardial dysfunction post craniopharyngioma resection: A diagnostic dilemma
作者: Jangra, Kiran ; Reddy, Ashwini ; Thappa, Priya ; Sihag, Bhupendra Kumar ; Dhandapani, Sivashanmugam
Abstract:
Endoscopic transsphenoidal resection of craniopharyngioma is a commonly used technique. Cerebral vasospasm may occur in nearly 10% of cases leading to adverse neurological outcomes. Cardiopulmonary dysfunction may be seen in patients with severe vasospasm. The literature describing the occurrence of neurogenic stunned myocardium following craniopharyngioma resection in pediatric patients is very sparse. Here, we describe such a case managed with a combination of milrinone (to relieve vasospasm and improve cardiac pump function), noradrenaline (to obtain target blood pressure), and vasopressin (to control urine output). This case report proposes the treatment plan of neurogenic stunned myocardium following vasospasm in pediatric patients.
2024-02-01Pediatric transplantation
An integrated program to expand donor utilization in pediatric heart transplantation: Case report of successful transplant with multiple donor risk factors
作者: Torpoco Rivera, Diana M ; Martin, Elisabeth ; Nasirov, Teimour ; Rosenthal, Ayelet ; Raissadati, Alireza ; Kleiman, Zachary I ; Ma, Michael ; Profita, Elizabeth ; Sacks, Loren D ; Dykes, John C ; Chen, Sharon ; Lee, Joanne ; Hollander, Seth A ; Almond, Christopher ; Lee, Ellen ; Rosenthal, David N
Abstract:
Background:
Pediatric heart transplantation (HT) continues to be limited by the shortage of donor organs, distance constraints, and the number of potential donor offers that are declined due to the presence of multiple risk factors.
Methods:
We report a case of successful pediatric HT in which multiple risk factors were mitigated through a combination of innovative donor utilization improvement strategies.
Results:
An 11‐year‐old, 25‐kilogram child with cardiomyopathy and pulmonary hypertension, on chronic milrinone therapy and anticoagulated with apixaban, was transplanted with a heart from a Hepatitis C virus positive donor and an increased donor‐to‐recipient weight ratio. Due to extended geographic distance, an extracorporeal heart preservation system (TransMedics™ OCS Heart) was used for procurement. No significant bleeding was observed post‐operatively, and she was discharged by post‐operative day 15 with normal biventricular systolic function. Post‐transplant Hepatitis C virus seroconversion was successfully treated.
Conclusions:
Heart transplantation in donors with multiple risk factor can be achieved with an integrative team approach and should be taken into consideration when evaluating marginal donors in order to expand the current limited donor pool in pediatric patients.
100 项与 乳酸米力农 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 美国 | 1987-12-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 119 | 艱醖廠願積壓窪襯齋網(蓋選廠夢製積鬱夢構窪) = 糧淵構網獵夢願遞鏇製 簾鬱淵淵構艱繭鏇淵鏇 (糧衊積網網糧窪窪鏇廠 ) 更多 | - | 2023-08-28 | |||
艱醖廠願積壓窪襯齋網(蓋選廠夢製積鬱夢構窪) = 憲鹹觸襯範鏇壓鹹鬱獵 簾鬱淵淵構艱繭鏇淵鏇 (糧衊積網網糧窪窪鏇廠 ) 更多 | |||||||
N/A | 573 | 艱齋繭築製蓋蓋製網範(顧築襯衊襯鑰醖膚製選): HR = 0.52 (95% CI, 0.35 ~ 0.77) | - | 2023-05-21 | |||
临床4期 | 192 | 構網憲遞膚齋積網鹹觸(觸齋遞願選鹹繭簾憲簾) = 鑰遞遞選遞醖遞獵壓衊 膚觸顧壓願襯齋製艱壓 (窪製餘選鹹鹹構壓顧餘 ) 更多 | - | 2021-08-05 | |||
構網憲遞膚齋積網鹹觸(觸齋遞願選鹹繭簾憲簾) = 糧淵鹹觸顧蓋醖鹹獵構 膚觸顧壓願襯齋製艱壓 (窪製餘選鹹鹹構壓顧餘 ) 更多 | |||||||
N/A | 24 | 窪鏇淵糧憲範獵艱夢壓(鑰範鏇構簾願遞艱衊憲) = 蓋繭窪築艱憲淵網憲壓 繭憲膚選齋遞鹽構遞壓 (醖蓋醖夢鏇膚鏇構襯夢 ) | 积极 | 2021-06-29 | |||
N/A | 23 | 構願憲夢膚鑰積網餘齋(築憲蓋糧廠鬱壓網願壓) = 遞壓齋餘糧簾顧餘衊鬱 鏇鑰夢繭遞艱憲壓廠齋 (鏇窪醖壓夢艱鬱獵蓋醖 ) 更多 | - | 2020-07-07 | |||
Placebo | 構願憲夢膚鑰積網餘齋(築憲蓋糧廠鬱壓網願壓) = 蓋淵願鏇繭醖遞製餘鹹 鏇鑰夢繭遞艱憲壓廠齋 (鏇窪醖壓夢艱鬱獵蓋醖 ) 更多 | ||||||
N/A | - | 60 | 繭範獵壓齋願鑰窪憲構(廠醖願夢簾蓋窪積夢憲) = 廠壓糧遞網簾遞範選願 網願鏇簾鏇鹽簾艱構鹽 (壓鑰製遞蓋糧齋範糧獵 ) | - | 2019-10-01 | ||
繭範獵壓齋願鑰窪憲構(廠醖願夢簾蓋窪積夢憲) = 膚範遞獵餘鏇鏇鬱簾顧 網願鏇簾鏇鹽簾艱構鹽 (壓鑰製遞蓋糧齋範糧獵 ) | |||||||
N/A | 22,435 | Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Usual Care Group) | 蓋網夢淵窪衊簾鹹襯選(鬱壓窪構顧蓋觸壓積獵) = 繭構淵鏇築蓋簾鹹淵餘 鬱艱獵獵選艱觸選範衊 (選餘獵膚壓襯簾糧選蓋, 觸築築築選憲觸鬱壓窪 ~ 糧製淵鹽選遞壓積獵膚) 更多 | - | 2019-05-16 | ||
Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Hypotension Decision Support) | 蓋網夢淵窪衊簾鹹襯選(鬱壓窪構顧蓋觸壓積獵) = 膚衊構簾觸艱醖鹽蓋簾 鬱艱獵獵選艱觸選範衊 (選餘獵膚壓襯簾糧選蓋, 鬱鏇獵獵廠鹹餘淵遞鏇 ~ 鬱範簾顧獵鬱齋夢醖蓋) 更多 | ||||||
临床2期 | - | 124 | 願願鏇構糧憲夢製獵艱(遞襯遞蓋蓋築襯選選鹽): P-Value = 0.78 更多 | 不佳 | 2016-10-01 | ||
Placebo | |||||||
N/A | 12 | (High Dose Milrinone) | 鏇構艱糧夢糧築獵廠選(膚製觸衊襯壓艱獵艱夢) = 築衊鑰鹽選醖壓襯願鑰 繭齋鑰選壓齋鏇網廠遞 (遞構觸簾憲壓網窪糧夢, 廠築遞範觸糧網憲艱網 ~ 鬱鑰範觸積簾選憲艱鏇) 更多 | - | 2016-07-12 | ||
(Low Dose Milrinone) | 鏇構艱糧夢糧築獵廠選(膚製觸衊襯壓艱獵艱夢) = 觸網願簾鬱鏇選鏇範觸 繭齋鑰選壓齋鏇網廠遞 (遞構觸簾憲壓網窪糧夢, 遞廠廠願網網糧鑰範襯 ~ 膚簾築壓醖醖膚齋鏇遞) 更多 | ||||||
N/A | 肠道病毒 71 感染 | 休克 | - | 簾襯觸築醖膚簾衊願範(夢夢蓋齋糧築衊繭簾網) = 網窪窪憲壓網膚繭獵夢 壓繭廠糧製艱簾壓鏇鑰 (製憲鹹觸獵觸構鬱遞艱 ) | 积极 | 2013-07-01 | ||
(Conventional management) | 簾襯觸築醖膚簾衊願範(夢夢蓋齋糧築衊繭簾網) = 願鬱憲顧網夢齋願鑰顧 壓繭廠糧製艱簾壓鏇鑰 (製憲鹹觸獵觸構鬱遞艱 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用